journal
Journals American Society of Clinical O...

American Society of Clinical Oncology Educational Book

https://read.qxmd.com/read/37319380/managing-a-long-and-winding-road-estrogen-receptor-positive-breast-cancer
#21
REVIEW
Michael Gnant, Nicholas C Turner, Cristina Hernando
We review key topics in the management of estrogen receptor (ER)-positive human epidermal growth factor receptor 2-negative breast cancer. The single biggest challenge in management of this disease is late relapse, and we review new methods for identifying which patients are at risk of late relapse and potential therapeutic approaches in clinical trials. CDK4/6 inhibitors have become a standard treatment option for high-risk patients in both the adjuvant setting and the first-line metastatic setting, and we review data on optimal treatment after progression on CDK4/6 inhibitors...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37311155/using-measurable-residual-disease-to-optimize-management-of-aml-all-and-chronic-myeloid-leukemia
#22
REVIEW
Simone E Dekker, Delphine Rea, Jean-Michel Cayuela, Isabell Arnhardt, Jessica Leonard, Michael Heuser
In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; describe the clinical relevance and medical decision making on the basis of MRD; compare and contrast the usage of MRD across AML, ALL, and CML; and discuss what patients need to know about MRD as it relates to their disease status and treatment. Finally, we discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37307515/new-opportunities-for-minimizing-toxicity-in-rectal-cancer-management
#23
JOURNAL ARTICLE
Alice M Couwenberg, Dimitrios N Varvoglis, Brian C Grieb, Corrie A M Marijnen, Kristen K Ciombor, Jose G Guillem
Advances in multimodal management of locally advanced rectal cancer (LARC), consisting of preoperative chemotherapy and/or radiotherapy followed by surgery with or without adjuvant chemotherapy, have improved local disease control and patient survival but are associated with significant risk for acute and long-term morbidity. Recently published trials, evaluating treatment dose intensification via the addition of preoperative induction or consolidation chemotherapy (total neoadjuvant therapy [TNT]), have demonstrated improved tumor response rates while maintaining acceptable toxicity...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37307513/the-times-they-are-a-changing-the-impact-of-next-generation-sequencing-on-diagnosis-classification-and-prognostication-of-myeloid-malignancies-with-focus-on-myelodysplastic-syndrome-aml-and-germline-predisposition
#24
REVIEW
Sandeep Gurbuxani, Michael J Hochman, Amy E DeZern, Akiko Shimamura
Myeloid malignancies are a manifestation of clonal expansion of hematopoietic cells driven by somatic genetic alterations that may arise in a potential background of deleterious germline variants. As next-generation sequencing technology has become more accessible, real-world experience has allowed integration of molecular genomic data with morphology, immunophenotype, and conventional cytogenetics to refine our understanding of myeloid malignancies. This has prompted revisions in the classification and the prognostication schema of myeloid malignancies and germline predisposition to hematologic malignancies...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37290034/current-therapeutic-targets-in-cancer-cachexia-a-pathophysiologic-approach
#25
JOURNAL ARTICLE
Kunal C Kadakia, Jill M Hamilton-Reeves, Vickie E Baracos
Significant progress in our understanding of cancer cachexia has occurred in recent years. Despite these advances, no pharmacologic agent has achieved US Food and Drug Administration approval for this common and highly morbid syndrome. Fortunately, improved understanding of the molecular basis of cancer cachexia has led to novel targeted approaches that are in varying stages of drug development. This article reviews two major thematic areas that are driving these pharmacologic strategies, including those targeting signal mediators at the level of the CNS and skeletal muscle...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37290032/next-generation-approaches-to-immuno-oncology-in-gi-cancers
#26
REVIEW
J Randolph Hecht, Jasmine Mitchell, Maria Pia Morelli, Gayathri Anandappa, James C Yang
Immunotherapy has only had a modest impact on the treatment of advanced GI malignancies. Microsatellite-stable colorectal cancer and pancreatic adenocarcinoma, the most common GI tumors, have not benefited from treatment with standard immune checkpoint inhibitors. With this huge unmet need, multiple approaches are being tried to overcome barriers to better anticancer outcomes. This article reviews a number of novel approaches to immunotherapy for these tumors. These include the use of novel checkpoint inhibitors such as a modified anti-cytotoxic T lymphocyte-associated antigen-4 antibody and antibodies to lymphocyte-activation gene 3, T cell immunoreceptor with immunoglobulin and ITIM domains, T-cell immunoglobulin-3, CD47, and combinations with signal transduction inhibitors...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37290027/patient-reported-outcomes-digital-health-and-the-quest-to-improve-health-equity
#27
JOURNAL ARTICLE
Joshua C Pritchett, Debra Patt, Gita Thanarajasingam, Anne Schuster, Claire Snyder
The theme of the 2023 American Society of Clinical Oncology Annual Meeting is Partnering With Patients: The Cornerstone of Cancer Care and Research. As we aim to partner with patients to improve their health care, digital tools have the potential to enhance patient-centered cancer care and make clinical research more accessible and generalizable. Using electronic patient-reported outcomes (ePROs) to collect patients' reports of symptoms, functioning, and well-being facilitates patient-clinician communication and improves care and outcomes...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37290016/embracing-myeloma-chimeric-antigen-receptor-t-from-scientific-design-to-clinical-impact
#28
JOURNAL ARTICLE
Hitomi Hosoya, Paula Rodriguez-Otero, Surbhi Sidana, Ivan M Borrello
Despite recent advancement of treatment strategies in multiple myeloma (MM), patients with relapsed/refractory MM disease, particularly after triple-class refractoriness, continue to have poor prognosis. Chimeric antigen receptor (CAR-T) cells were developed and applied to improve outcomes in this setting, and two products, idecabtagene vicleucel and ciltacabtagene autoleucel, both targeting B-cell maturation antigen, have been approved by the Food and Drug Administration in the United States and European Medicines Agency in Europe...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37285556/managing-adverse-effects-associated-with-poly-adp-ribose-polymerase-inhibitors-in-ovarian-cancer-a-synthesis-of-clinical-trial-and-real-world-data
#29
REVIEW
Michael Friedlander, Yeh Chen Lee, William P Tew
The use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy is standard care in the management of patients with various malignancies including ovarian, breast, prostate, and pancreatic cancers. PARP inhibitors have been approved in different settings for patients with specific hereditary pathogenic variants, most notably homologous recombination repair pathways such as BRCA1 and BRCA2 genes. The vast experience with PARP inhibitors (olaparib, niraparib, rucaparib) has been in the management of epithelial ovarian cancer...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37279437/team-based-care-in-oncology-the-impact-of-the-advanced-practice-provider
#30
JOURNAL ARTICLE
Todd Pickard, Stephanie Williams, Eric Tetzlaff, Camille Petraitis, Heather Hylton
Integration of APPs into care teams affects quality and safety for the oncology patient. Learn the best practices and understand the concepts of onboarding, orientation, mentorship, scope of practice, and top of license. Review how productivity and other incentive programs can be adapted to integrate APPs and focus on team-based metrics.
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37267515/improving-quality-of-life-during-chemotherapy-cannabinoids-cryotherapy-and-scalp-cooling
#31
REVIEW
Alissa Michel, Richard T Lee, Elahe Salehi, Melissa K Accordino
There have been significant advances in the treatment of cancer in the past decade. However, patients continue to suffer from significant side effects of antineoplastic agents that greatly affect their quality of life (QOL), including chemotherapy-induced nausea and vomiting (CINV), chemotherapy-induced peripheral neuropathy (CIPN), and chemotherapy-induced alopecia (CIA). This review aims to provide an updated overview of emerging strategies for the management and prevention of these immediate and long-lasting side effects...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37267275/rekindling-joy-in-medicine-through-thoughtful-communication-a-practical-guide
#32
REVIEW
Tara Sanft, Eric Winer
Joy in medicine, or the loss of it, is a popular topic of conversation, even more so since the pandemic. Burnout in oncology is common and diminishes the satisfaction of practicing medicine. One of the challenges clinicians face is the way in which modern clinical practice takes us away from what we find most meaningful in our work: time with patients. Strategies like being kind, expressing gratitude, and using effective communication skills can establish more connection with our colleagues and our patients, and, in turn, result in a more joyful work environment...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37262395/frontline-management-of-nodal-peripheral-t-cell-lymphomas
#33
JOURNAL ARTICLE
Henry S Ngu, Kerry J Savage
Peripheral T-cell lymphomas (PTCLs) represent only 10%-15% of all non-Hodgkin lymphoma but encompass a diverse group of diseases with over 30 different subtypes. As a result of both disease heterogeneity and rarity, therapeutic progress of PTCLs has lagged behind B-cell lymphomas with very few randomized controlled studies to guide management. The most common subtypes are the so-called nodal PTCLs: PTCL-not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), and nodal T follicular helper cell lymphoma (TFHL) lymphoma, the latter of which includes angioimmunoblastic T-cell lymphoma...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37257140/therapy-sequencing-in-patients-with-advanced-neuroendocrine-neoplasms
#34
REVIEW
Rachel P Riechelmann, Rodrigo G Taboada, Victor Hugo F de Jesus, Michael Iglesia, Nikolaos A Trikalinos
Neuroendocrine neoplasms (NENs) comprise a beautifully complicated, exciting landscape of histologies and clinical behaviors. However, the nuanced complexity of low- and high-grade variants can easily overwhelm both patients and providers. In this chapter, we review the ever-expanding literature on both functioning and nonfunctioning small bowel and pancreatic NENs, touching on somatostatin analogs, hepatic-directed therapies, small molecules, radiopharmaceuticals, immunotherapy, cytotoxic chemotherapy, and new promising agents...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37253213/fear-of-saying-no-fosno-setting-boundaries-with-our-patients-and-ourselves
#35
JOURNAL ARTICLE
Monica S Chatwal, Arif H Kamal, Jonathan M Marron
Cancer is an inherently complex and intense medical condition that often requires prolonged treatment and surveillance over years. Treatments can lead to frequent side effects and anxiety, requiring constant communication and follow-up with patients. Oncologists have the unique privilege of developing close relationships with their patients that evolve through the course of their disease. The advent of newer technology and the changing landscape of medicine have drastically altered how oncologists now manage patient needs...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37253211/state-of-the-art-multidisciplinary-management-of-oligometastatic-renal-cell-carcinoma
#36
REVIEW
Shawn Dason, Kristine Lacuna, Raquibul Hannan, Eric A. Singer, Karie Runcie
Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is distinguishable from oligoprogressive RCC, which describes progression of disease to a limited number of sites while receiving systemic therapy. Cytoreductive nephrectomy and metastasectomy are common surgical considerations in OM-RCC, and indications are discussed in this review. It is evident that stereotactic ablative radiotherapy is effective in RCC and is being applied increasingly in the oligometastatic setting...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37235822/artificial-intelligence-in-clinical-oncology-from-data-to-digital-pathology-and-treatment
#37
JOURNAL ARTICLE
Kirthika Senthil Kumar, Vanja Miskovic, Agata Blasiak, Raghav Sundar, Alessandra Laura Giulia Pedrocchi, Alexander T Pearson, Arsela Prelaj, Dean Ho
Recently, a wide spectrum of artificial intelligence (AI)-based applications in the broader categories of digital pathology, biomarker development, and treatment have been explored. In the domain of digital pathology, these have included novel analytical strategies for realizing new information derived from standard histology to guide treatment selection and biomarker development to predict treatment selection and response. In therapeutics, these have included AI-driven drug target discovery, drug design and repurposing, combination regimen optimization, modulated dosing, and beyond...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37235819/early-onset-gi-cancers-rising-trends-genetic-risks-novel-strategies-and-special-considerations
#38
JOURNAL ARTICLE
Emily Harrold, Alicia Latham, Naveen Pemmaraju, Christopher H Lieu
Cancers in young adults (commonly described as early-onset [EO] cancer) represent a group of malignancies that have unique and challenging biology and genetic, treatment, social, and psychological implications. Even more concerning is a rising trend of EO cancers in multiple tumor types. Research and investigation in EO cancers will help elucidate mechanisms of carcinogenesis, differences in biology and response to treatment, and the need for multidisciplinary care to ensure comprehensive treatment and support for young patients...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37229642/antibody-drug-conjugates-in-gynecologic-cancer
#39
REVIEW
Hannah C Karpel, Sachia Stonefeld Powell, Bhavana Pothuri
The present article reviews the current evidence for antibody-drug conjugates (ADCs) in gynecologic cancer. ADCs consist of a highly selective monoclonal antibody for a tumor-associated antigen and a potent cytotoxic payload conjugated through a linker. Overall, the toxicity profiles of ADCs are manageable. Ocular toxicity is a known class effect of some ADCs and is managed with prophylactic corticosteroid and vasoconstrictor eye drops as well as dose interruptions/holds and dose modifications. In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRα), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial...
May 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37229626/a-brain-a-heart-and-the-courage-balancing-benefit-and-toxicity-of-immunotherapy-in-melanoma
#40
JOURNAL ARTICLE
Yen-Chou Chen, Muhammad Jaffer, Lylybell Zhou, Javid Moslehi, Peter A Forsyth, Leslie A Fecher
The overall survival of advanced melanoma has improved dramatically. Immunotherapies, specifically checkpoint inhibitors, have played a large role in this improvement. These agents have also shown benefit in the adjuvant setting, are approved for treatment of resected stage II, III, and IV melanoma, and play an evolving role in the neoadjuvant setting. Although generally well tolerated, immune-related adverse events occur and can be severe. Here we focus on some severe and potentially long term toxicities, including cardiovascular and neurologic toxicities...
May 2023: American Society of Clinical Oncology Educational Book
journal
journal
46604
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.